TNSN04023A1 - Formulation de suspension orale stabilisee - Google Patents

Formulation de suspension orale stabilisee

Info

Publication number
TNSN04023A1
TNSN04023A1 TNP2004000023A TNSN04023A TNSN04023A1 TN SN04023 A1 TNSN04023 A1 TN SN04023A1 TN P2004000023 A TNP2004000023 A TN P2004000023A TN SN04023 A TNSN04023 A TN SN04023A TN SN04023 A1 TNSN04023 A1 TN SN04023A1
Authority
TN
Tunisia
Prior art keywords
formulation
oral suspension
agent
stabilized oral
thixotropic
Prior art date
Application number
TNP2004000023A
Other languages
English (en)
Inventor
Wei Lu Guang
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN04023A1 publication Critical patent/TNSN04023A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Abstract

IL EST PROPOSE DES COMPOSITIONS PHARMACEUTIQUES POUVANT ETRE ADMINISTREES PAR VOIE ORALE. COMPRENANT UN MEDICAMENT A FAIBLE HYDROSOLUBILITE EN SUSPENSION DANS UN VEHICULE LIQUIDE AQUEUX COMPRENANT UN AGENT MOUILLANT; UN AGENT EPAISSISSANT THIXOTROPE ET UN AGENT INORGANIQUE DE MISE EN SUSPENSION. LES COMPOSITIONS SONT THIXOTROPE; SUBSTANTIELLEMENT DEFLOCULEES; ET SUBSTANTIELLEMENT STABLES PHYSIQUEMENT.
TNP2004000023A 2001-08-06 2004-02-05 Formulation de suspension orale stabilisee TNSN04023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31037201P 2001-08-06 2001-08-06
PCT/US2002/024746 WO2003013473A1 (fr) 2001-08-06 2002-08-05 Preparation de suspension orale stabilisee

Publications (1)

Publication Number Publication Date
TNSN04023A1 true TNSN04023A1 (fr) 2006-06-01

Family

ID=23202195

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000023A TNSN04023A1 (fr) 2001-08-06 2004-02-05 Formulation de suspension orale stabilisee

Country Status (34)

Country Link
US (2) US20030108575A1 (fr)
EP (1) EP1414409B1 (fr)
JP (1) JP2005500363A (fr)
KR (1) KR20040025740A (fr)
CN (1) CN1287768C (fr)
AP (1) AP1817A (fr)
AT (1) ATE353627T1 (fr)
BR (1) BR0211736A (fr)
CA (1) CA2454173A1 (fr)
CO (1) CO5560559A2 (fr)
CY (1) CY1106548T1 (fr)
DE (1) DE60218175T2 (fr)
DK (1) DK1414409T3 (fr)
EA (1) EA007901B1 (fr)
EC (1) ECSP044974A (fr)
ES (1) ES2280560T3 (fr)
GE (1) GEP20074027B (fr)
HK (1) HK1069542A1 (fr)
HR (1) HRP20040118A2 (fr)
IL (1) IL159551A0 (fr)
IS (1) IS7126A (fr)
MA (1) MA27054A1 (fr)
MX (1) MXPA04001109A (fr)
MY (1) MY135119A (fr)
NZ (1) NZ530844A (fr)
OA (1) OA12646A (fr)
PL (1) PL366382A1 (fr)
PT (1) PT1414409E (fr)
SI (1) SI1414409T1 (fr)
TN (1) TNSN04023A1 (fr)
UA (1) UA80682C2 (fr)
WO (1) WO2003013473A1 (fr)
YU (1) YU7404A (fr)
ZA (1) ZA200400639B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20050036956A1 (en) * 2003-08-15 2005-02-17 Lin Fei Non-aqueous liquid tooth whitening composition
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
US20050266031A1 (en) * 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
DK2018153T3 (da) 2006-04-26 2012-07-23 Rosemont Pharmaceuticals Ltd Flydende orale sammensætninger
CN100434072C (zh) * 2006-06-19 2008-11-19 西安交通大学 具有抗炎性作用及改善血液流变性和抑制血栓形成的药物
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
WO2009133431A1 (fr) * 2008-04-30 2009-11-05 Wockhardt Research Centre Compositions liquides orales de rhéine ou de diacéréine
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
WO2011107855A2 (fr) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
PL2544532T3 (pl) 2010-03-12 2017-08-31 Monsanto Technology Llc Agrochemiczne kompozycje żelowe
DK2575784T3 (en) * 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
EP2462922A1 (fr) * 2010-12-10 2012-06-13 Bioprojet Nouvelle forme d'administration pour inhibiteurs de l'enképhalinase
WO2012099142A1 (fr) * 2011-01-18 2012-07-26 千寿製薬株式会社 Composition liquide aqueuse de bromfénac qui est efficace comme conservateur
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
JP2018516279A (ja) * 2015-05-29 2018-06-21 コーダドース・インコーポレーテッド 経口投与用のセレコキシブの液状配合物
US11083780B2 (en) 2015-07-20 2021-08-10 The Brigham And Women's Hospital, Inc. Shear-thinning compositions as an intravascular embolic agent
CN105902409B (zh) * 2016-05-13 2019-03-05 广东龙湖科技股份有限公司 一种温和且具有触变性的牙膏
CN109843331A (zh) * 2016-10-19 2019-06-04 萨恩帕斯药物有限公司 Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用
WO2019070818A2 (fr) * 2017-10-04 2019-04-11 Panacea Biomatx, Inc. Suspensions de produits pharmaceutiques encapsulés et leurs procédés de fabrication et d'utilisation
CN112402376A (zh) * 2019-08-22 2021-02-26 上海上药信谊药厂有限公司 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法
CN117883379A (zh) * 2021-02-12 2024-04-16 浙江贝灵生物医药有限公司 一种口服碱性溶媒组合物及其制备方法与应用
WO2022185338A1 (fr) * 2021-03-05 2022-09-09 Alkem Laboratories Limited Suspension orale stable de célécoxib et son procédé de préparation

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
KR920702616A (ko) * 1989-06-13 1992-10-06 원본미기재 약제를 전달하기 위한 무수 오일-기제된 액체 현탁액
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
CA2276945C (fr) * 1993-11-30 2006-08-01 G.D. Searle & Co. Pyrazolyle benzenesulfonamide tricyclique-substitue et leurs compositions pharmaceutiques
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU2424895A (en) * 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP1125932A3 (fr) * 1994-07-27 2001-08-29 G.D. Searle & Co. Thiazoles substitués destinés au traitement de l'inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) * 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5696143A (en) * 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
ES2139959T3 (es) * 1994-10-27 2000-02-16 Merck Frosst Canada Inc Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2211320C (fr) * 1995-01-31 2007-03-20 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones utilises comme inhibiteurs de cyclooxygenase-2
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en) * 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CN1174970C (zh) * 1995-05-25 2004-11-10 G·D·瑟尔公司 3-卤代烷基-1h-吡唑的制备方法
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) * 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
NZ327044A (en) * 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) * 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
DE69739003D1 (de) * 1996-04-12 2008-10-30 Searle Llc Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5741798A (en) * 1996-06-03 1998-04-21 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751964B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5972950A (en) * 1996-10-08 1999-10-26 Laboratories Upsa 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en) * 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) * 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
ATE250576T1 (de) * 1996-12-10 2003-10-15 Searle & Co Substituierte pyrrolylverbindungen zur behandlung von entzündungen
US5973191A (en) * 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6046217A (en) * 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6040450A (en) * 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr) * 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PT1071745E (pt) * 1998-04-24 2004-11-30 Merck & Co Inc Processo para sintetizar inibidores cox-2
US6077869A (en) * 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6077868A (en) * 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
WO2001030342A1 (fr) * 1999-10-20 2001-05-03 Board Of Trustees Of Southern Illinois University Utilisation des flavones comme inhibiteurs de l'oxyde nitrique synthase inductibles, comme inhibiteurs de cyclooxygenase-2 et comme activateurs des canaux potassiques
ES2236007T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
CA2406226A1 (fr) * 2000-04-18 2001-10-25 Pharmacia Corporation Formulation a effet therapeutique rapide contenant un inhibiteur selectif de la cyclooxygenase-2
WO2002005799A2 (fr) * 2000-07-13 2002-01-24 Pharmacia Corporation Composes vasomodulateurs et inhibiteurs selectifs de la cyclo-oxygenase-2 pour le traitement des douleurs generalisees et des cephalees
GB0617119D0 (en) * 2006-08-31 2006-10-11 Renovo Ltd Method of prognosis

Also Published As

Publication number Publication date
CN1287768C (zh) 2006-12-06
ATE353627T1 (de) 2007-03-15
JP2005500363A (ja) 2005-01-06
GEP20074027B (en) 2007-02-12
PT1414409E (pt) 2007-03-30
EA200400148A1 (ru) 2004-08-26
HK1069542A1 (en) 2005-05-27
CN1549704A (zh) 2004-11-24
AP1817A (en) 2008-01-07
DK1414409T3 (da) 2007-06-11
YU7404A (sh) 2006-08-17
HRP20040118A2 (en) 2004-06-30
MY135119A (en) 2008-02-29
MXPA04001109A (es) 2005-02-17
US20090081309A1 (en) 2009-03-26
CY1106548T1 (el) 2012-01-25
OA12646A (en) 2006-06-16
IL159551A0 (en) 2004-06-01
US20030108575A1 (en) 2003-06-12
CA2454173A1 (fr) 2003-02-20
WO2003013473A1 (fr) 2003-02-20
CO5560559A2 (es) 2005-09-30
KR20040025740A (ko) 2004-03-25
AP2004002969A0 (en) 2004-03-31
SI1414409T1 (sl) 2007-06-30
NZ530844A (en) 2005-11-25
EP1414409A1 (fr) 2004-05-06
DE60218175T2 (de) 2007-11-22
EP1414409B1 (fr) 2007-02-14
ES2280560T3 (es) 2007-09-16
BR0211736A (pt) 2004-09-28
DE60218175D1 (de) 2007-03-29
MA27054A1 (fr) 2004-12-20
UA80682C2 (en) 2007-10-25
PL366382A1 (en) 2005-01-24
IS7126A (is) 2004-01-26
EA007901B1 (ru) 2007-02-27
ZA200400639B (en) 2005-04-08
ECSP044974A (es) 2004-03-23

Similar Documents

Publication Publication Date Title
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
ITMI20021392A1 (it) Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
UY27320A1 (es) Nuevas composiciones farmacéuticas
FR2830447B1 (fr) Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
AU2003304237A8 (en) Gel-stabilized nanoparticulate active agent compositions
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
ATE541562T1 (de) Ibuprofen-suspension
EP1993567A4 (fr) Préparations de gallium administrables per os et leurs méthodes d'utilisation
TR200401906T4 (tr) Kendini emülsifiye ilaç sistemi, yağ ajanı seçime bağlıdır.
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
CA2417935A1 (fr) Medicament anti-inflammatoire
PE20030545A1 (es) Formulaciones de jarabe de ribavirina
UY27373A1 (es) Formulaciones de interferón beta-humano
FR2843301B1 (fr) Forme galenique pour la delivrance colique de principes actifs
FR2839645B1 (fr) Systeme multilamellaire pour l'administration de substances actives (en particulier des medicaments) par ingestion par la voie orale
CA2164799A1 (fr) Compositions a base d'un systeme abrasif et d'un systeme tensio-actif
CR7245A (es) Formulacion de suspension oral estabilizada
FR2809958B1 (fr) Composition pharmaceutique sous forme liquide destinee a l'administration par voie orale d'un principe actif, ayant un gout desagreable, notamment un gout amer
MY152490A (en) New oral formulation
TH20307EX (th) สารสูตรผสมอิมัลชันชนิดใหม่
CO4910116A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles